Antagonists

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (15:14, 22 November 2023) (edit) (undo)
 
(One intermediate revision not shown.)
Line 1: Line 1:
-
<StructureSection load='4dkl' size='400' side='right' caption='Crystal structure of the mu-opioid receptor bound to a morphinan antagonist, cholesterol, PEG 400, sulfate, mono-oleoyl-glycerol and Cl- ion (PDB entry [[4dkl]])' scene=4dkl/Overall_structure/1''>
+
<StructureSection load='4dkl' size='340' side='right' caption='Crystal structure of the mu-opioid receptor bound to a morphinan antagonist, cholesterol, PEG 400, sulfate, mono-oleoyl-glycerol and Cl- ion (PDB entry [[4dkl]])' scene=4dkl/Overall_structure/1''>
-
'''Under construction'''
+
See also [[Types of ligands]] and [[Signal transduction]].
See also [[Types of ligands]] and [[Signal transduction]].

Current revision

Crystal structure of the mu-opioid receptor bound to a morphinan antagonist, cholesterol, PEG 400, sulfate, mono-oleoyl-glycerol and Cl- ion (PDB entry 4dkl)

Drag the structure with the mouse to rotate

References

  1. Turski L, Huth A, Sheardown M, McDonald F, Neuhaus R, Schneider HH, Dirnagl U, Wiegand F, Jacobsen P, Ottow E. ZK200775: a phosphonate quinoxalinedione AMPA antagonist for neuroprotection in stroke and trauma. Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10960-5. PMID:9724812
  2. Walters MR, Kaste M, Lees KR, Diener HC, Hommel M, De Keyser J, Steiner H, Versavel M. The AMPA antagonist ZK 200775 in patients with acute ischaemic stroke: a double-blind, multicentre, placebo-controlled safety and tolerability study. Cerebrovasc Dis. 2005;20(5):304-9. Epub 2005 Aug 30. PMID:16131799 doi:10.1159/000087929

Proteopedia Page Contributors and Editors (what is this?)

Alexander Berchansky

Personal tools